DSMB clears third pediatric patient for dosing in ongoing NGN-401 Phase 1/2 clinical trial for Rett syndrome; On track to dose third pediatric patient in early 1Q:24
CTA clearance obtained from UK MHRA for NGN-401
Ended 2023 in a strong financial position with approximately $200 million in cash and runway into 2H:26
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.